ClinicalTrials.gg
Not yet recruitingNCT07623928MANOEUVREUpdated Jun 3, 2026

Developing a Virtual Reality-assisted Intervention for Emotion Regulation Difficulties in Psychosis

An interventional study of MANOEUVRE therapy in Psychosis, SCHIZOPHRENIA 1 (Disorder) and Schizophrenia and Related Disorders, sponsored by King's College London. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by King's College London · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Psychotic Disorders by King's College London — 12 open to participants now, 12 under way, none of them phase 3. Psychotic Disorders · King's College London.

Planned enrollment
13th of 18
15 · median 24
Started
2027
the only one that year
No phase
15 of 26
5 open now
Primary completion
2028-05
later than 7 of 11 live
Registered
23rd of 26
by date

Among the 26 studies in Psychotic Disorders by King's College London, this one is the 13th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2027, is one of 15 with no phase, reaches primary completion later than 7 of the 11 other live ones, and was the 23rd registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

12 of the 26 studies in Psychotic Disorders by King's College London are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Psychotic Disorders by King's College London, or all of them as a file.
02

Study summary

Supporting people with psychosis to manage their emotions using virtual reality

Many people who have experienced psychosis feel overwhelmed by their emotions. Emotions get in the way of doing what matters to them. They want support to manage emotions differently. There is evidence that people with psychosis find talking therapies that teach skills for managing emotions helpful. People said it helped them to understand and manage their emotions. However, they also wanted more help to apply skills they learned to their lives.

It is hard to help people to use therapy skills in real-life situations. Therapists cannot be present when the skills are needed. One solution is to use virtual reality (VR) to bridge the gap between the clinic and real-life. VR involves using a headset to see and hear a very life-like computer-generated simulation of everyday life situations. People with psychosis find VR therapies engaging and helpful. It can feel safer to try things out in VR.

Guided by the feedback of people with psychosis, this research will evaluate a novel therapy to help people with psychosis manage their emotions. Face-to- face therapy will be combined with VR so that people can practice emotion regulation skills safely with "live" coaching from a therapist. This should support people to use these skills when they need them.

Fifteen people with psychosis will be offered the therapy. Everyone will be asked what they think of it and complete questionnaires before and after therapy to see what impact it had on their lives.

A lived experience advisory group will support all aspects of the research process.

Read the detailed description

Background Many people with psychosis report difficulties understanding and managing their emotions (emotion regulation difficulties), yet evidence-based interventions are lacking. Brief interventions that teach emotion regulation skills show promise but service users report wanting additional support to apply what they have learned in therapy to their lives.

Aim: To test the initial feasibility and acceptability of a VR-assisted therapy (called MANaging emOtions in Everyday life Using Virtual REality; MANOEUVRE) for emotion regulation difficulties in psychosis

Methods A mixed methods case series will be undertaken. The study will recruit people with psychosis from NHS community care teams (in England). Assessments will be at baseline, post therapy and 3-month follow up. Feasibility and acceptability of a future trial will be assessed based on uptake/ recruitment, data completeness and qualitative feedback. Feasibility and assessment of the therapy will be assessed based on adherence, acceptability (sessional feedback ratings, qualitative interview feedback, side effect and satisfaction ratings), safety (adverse effects), implementation resources and fidelity.

Participants will complete measures of emotion regulation difficulties, adaptive emotion regulation skill use, psychological distress, personal recovery goal achievement and quality of life. To assess feasibility, individual-level changes will be calculated using the reliable change index to assess whether changes are more likely to reflect measurement error or actual clinical change. Group-level changes will be assessed using means and standard deviations and effect sizes (Cohen's d) with confidence intervals . A post therapy semi-structured interview will explore participants' experience of receiving MANOEUVRE.

03

Conditions studied

  • Psychosis
  • SCHIZOPHRENIA 1 (Disorder)
  • Schizophrenia and Related Disorders

Keywords

  • Emotion regulation
  • Psychosis
  • Virtual reality
  • Schizophrenia spectrum disorders
  • Virtual reality exposure therapy
  • Psychotherapy
  • Dialectical behaviour therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently under the care of South London and Maudsley (SLaM) National Health Service (NHS) outpatient services.
  • Clinical diagnosis of psychosis (schizophrenia spectrum disorder) (as assessed by their clinical team)
  • Willing to have the interview audio recorded (if taking part in post therapy interview)
  • Willing and able to provide to participate in the study (as assessed by their clinical team)

Exclusion criteria

Exclusion Criteria:

  • Clinical presentation (e.g., immediate serious risk to self) (as assessed by their clinical team)
  • History of photosensitive epilepsy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Other
    MANOEUVRE therapy

    Other: MANOEUVRE therapy

Interventions

  • OtherMANOEUVRE therapy

    Virtual reality assisted psychological therapy for emotion regulation difficulties

06

What researchers measure

Primary outcomes

  1. Difficulties in Emotion Regulation Scale 16 item version (DERS-16)

    Self reported emotion regulation difficulties

    Time frame: Pre therapy, immediately after therapy, 3 month follow up

Other outcomes

  1. DBT Ways of Coping Checklist - DBT Skills Subscale

    Adaptive use of emotion regulation skills

    Time frame: Pre therapy, immediately after therapy, follow up

  2. Clinical Outcomes in Routine Evaluation-10 item version (CORE-10)

    Psychological distress

    Time frame: Pre therapy, immediately after therapy, 3 month follow up

  3. Goal Attainment Scaling (GAS)

    Personal recovery goal achievement

    Time frame: Pre therapy, immediately after therapy, 3 month follow up

  4. Recovering Quality of Life (ReQoL-10)

    Quality of life

    Time frame: Pre therapy, immediately after therapy, 3 month follow up

07

Study locations

1 site
  • Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London
    London, Greater London SE5 8AF, United Kingdom
08

References and documents

Publications

  • Lawlor C, Vitoratou S, Duffy J, Cooper B, De Souza T, Le Boutillier C, Carter B, Hepworth C, Jolley S. Managing emotions in psychosis: Evaluation of a brief DBT-informed skills group for individuals with psychosis in routine community services. Br J Clin Psychol. 2022 Sep;61(3):735-756. doi: 10.1111/bjc.12359. Epub 2022 Feb 7. PubMed 35130354 ↗
  • Lawlor C, Hepworth C, Smallwood J, Carter B, Jolley S. Self-reported emotion regulation difficulties in people with psychosis compared with non-clinical controls: A systematic literature review. Clin Psychol Psychother. 2020 Mar;27(2):107-135. doi: 10.1002/cpp.2408. Epub 2020 Feb 12. PubMed 31661593 ↗

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results after deidentification

Time frame: After publication

Access criteria: The final anonymised study dataset will be available to other researchers at the end of the programme provided that does not compromise confidentiality.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2027; primary completion for May 2028, 8 months later.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 8 months is below that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 3, 2026
StartEst.
Sep 1, 2027
Primary completionEst.
May 1, 2028
CompletionEst.
Nov 1, 2028
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07623928
Collaborators
South London and Maudsley NHS Foundation Trust
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Sep 1, 2027 (estimated)
Primary completion
May 1, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Jun 3, 2026

Study contacts

Dr Caroline Lawlor
Contact
caroline.lawlor@kcl.ac.uk
+44 7388 960630
Professor Dame Til Wykes
Contact
Til.Wkyes@kcl.ac.uk
+44 20 7848 0596
Professor Dame Til Wykes
study chair · King's College London
Professor Matteo Cella
study director · King's College London
Dr Caroline Lawlor
principal investigator · King's College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion